ClinicalTrials.gg
CompletedNCT07404579Updated May 29, 2026

Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults

A Phase 2 interventional study of HRS-9190 and HRS-9190 in Neuromuscular Blockade, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Rocuronium. The primary objective is to measure the duration from the last dose of the study drug until the recovery of neuromuscular function to a specific level (TOFr ≥ 90%). Secondary objectives include evaluating the onset time and duration of action following each dose, the total time adequate muscle relaxation is maintained during surgery, and the detailed pattern of neuromuscular recovery. Safety assessments will include monitoring of adverse events, vital signs, laboratory parameters, and other safety indicators throughout the study period. The hypothesis of this study is that HRS-9190 for Injection could provide effective neuromuscular relaxation, with a satisfied safety profile in the target patient population.

02

Conditions studied

  • Neuromuscular Blockade
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Subjects requiring elective general anesthesia surgery
  3. Meet specified age and (BMI) criteria
  4. Conform to the ASA Physical Status Classification
  5. Use of highly effective for a specified period if applicable

Exclusion criteria

Exclusion Criteria:

  1. Scheduled for specific high-risk surgical procedures
  2. History of significant neuromuscular, cardiovascular, respiratory, or neurological disorders
  3. History of conditions affecting drug metabolism or anesthesia risk
  4. Abnormal laboratory values indicating significant clinical abnormalities
  5. Positive serology for specified infectious diseases
  6. Known to related medications
  7. Recent use of medications interfering with neuromuscular function
  8. History of mental illness, cognitive impairment, or epilepsy
  9. Participation in another clinical trial within a specified period
  10. Any other condition deemed unsuitable by the investigator
  11. Pregnant or nursing women
  12. Unwilling to use during the specified period
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Treatment group A: HRS-9190 under Inhalational Anesthesia

    Drug: HRS-9190

  • Experimental
    Treatment group B: HRS-9190 under Inhalational Anesthesia

    Drug: HRS-9190

  • Experimental
    Treatment group C: HRS-9190 under Intravenous Anesthesia

    Drug: HRS-9190

  • Experimental
    Treatment group D: HRS-9190 under Intravenous Anesthesia

    Drug: HRS-9190

  • Active comparator
    Treatment group E: Rocuronium under Inhalational Anesthesia

    Drug: Rocuronium

  • Active comparator
    Treatment group F: Rocuronium under Intravenous Anesthesia.

    Drug: Rocuronium

Interventions

  • HRS-9190; high dose(under Inhalational Anesthesia)

  • HRS-9190; low dose(under Inhalational Anesthesia)

  • HRS-9190; high dose(under Intravenous Anesthesia)

  • HRS-9190; low dose(under Intravenous Anesthesia)

  • Rocuronium(under Inhalational Anesthesia).

  • Rocuronium(under Intravenous Anesthesia)

06

What researchers measure

Primary outcomes

  1. Time from Last Dose to Recovery of TOFr to 0.9

    The duration (in minutes) from the administration of the last dose of the neuromuscular blocking agent to the recovery of the Train-of-Four ratio (TOFr) to 90% or greater

    Time frame: From the administration of the last dose of the study drug until TOFr ≥ 0.9 is achieved, assessed intraoperatively and in the recovery period, up to 2 hours.

Secondary outcomes

  1. Duration of Action after Bolus Dose(s)

    The time (in minutes) from each bolus administration (including the initial dose for induction) to: 1) the start of T1 recovery; 2) recovery of T1 to 10% of baseline; 3) recovery of T1 to 25% of baseline.

    Time frame: For each bolus dose: from administratin until specified recovery points, assessed intraoperatively, up to 2 hours.

  2. Time from Last Dose to Specific TOFr Recovery Milestones

    The time (in minutes) from the last dose to the recovery of TOFr to 0.4 and to 0.7.

    Time frame: From the administration of the last dose of the study drug until specified TOFr values are achieved, assessed intraoperatively and in recovery, up to 2 hours.

  3. Percentage of Time with Target Neuromuscular Block

    The proportion (%) of the total drug administration period during which adequate surgical relaxation (T1 ≤ 25% of baseline) is maintained.

    Time frame: From the first administration of the study drug until the end of the last maintenance dose requirement, assessed intraoperatively, up to 6 hours.

  4. Time to Successful Airway Device Placement

    The time (in minutes) from the administration of the study drug for induction to the completion of tracheal intubation or laryngeal mask placement.

    Time frame: From administration of the initial intubating dose to completion of tracheal intubation or laryngeal mask insertion, assessed at induction, approximately 2-5 minutes.

  5. Onset Time after Bolus Dose(s)

    The time (in minutes) from each bolus administration (including for induction) to the time of maximum T1 depression (peak effect).

    Time frame: For each bolus dose: from administration to maximum T1 depression, assessed intraoperatively, up to 6 hours.

  6. Time from Last Dose to Airway Device Removal

    The time (in minutes) from the last dose of the study drug to the removal of the tracheal tube or laryngeal mask.

    Time frame: From the administration of the last dose of the study drug to tracheal extubation or laryngeal mask removal, assessed at the end of surgery until device removal, up to 2 hours.

  7. Recovery Index

    The recovery time (in minutes) for T1 to recover from 25% to 75% of baseline, and from 5% to 95% of baseline, following the last dose.

    Time frame: After the last dose: from T1=25% to T1=75%, and from T1=5% to T1=95%, assessed intraoperatively and in recovery, up to 2 hours.

  8. Anesthesiologist's Overall Satisfaction Score

    The overall satisfaction score regarding the quality and ease of neuromuscular management, rated by the attending anesthesiologist using a predefined scale.

    Time frame: Assessed at the end of the surgical procedure, within 1 hour.

  9. Surgeon's Overall Satisfaction Score

    The overall satisfaction score regarding surgical conditions related to muscle relaxation, rated by the operating surgeon using a predefined scale.

    Time frame: Assessed at the end of the surgical procedure, within 1 hour.

07

Study locations

2 sites
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450004, China
  • Shanghai Jiaotong University School of Medicine, Renji Hospital
    Shanghai, Shanghai Municipality 200000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in May 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 11, 2026
StartActual
Mar 6, 2026
Primary completionActual
May 15, 2026
CompletionActual
May 26, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07404579
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Mar 6, 2026
Primary completion
May 15, 2026
Completion
May 26, 2026
Last update
May 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9190

Start the discussion